USH2284H1 - Vaccines for protecting against influenza - Google Patents
Vaccines for protecting against influenza Download PDFInfo
- Publication number
- USH2284H1 USH2284H1 US12/768,662 US76866210A USH2284H US H2284 H1 USH2284 H1 US H2284H1 US 76866210 A US76866210 A US 76866210A US H2284 H USH2284 H US H2284H
- Authority
- US
- United States
- Prior art keywords
- virus
- vaccine
- strain
- influenza
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/768,662 USH2284H1 (en) | 2009-04-27 | 2010-04-27 | Vaccines for protecting against influenza |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21478709P | 2009-04-27 | 2009-04-27 | |
US21619809P | 2009-05-13 | 2009-05-13 | |
US23862809P | 2009-08-31 | 2009-08-31 | |
US27966509P | 2009-10-22 | 2009-10-22 | |
US12/768,662 USH2284H1 (en) | 2009-04-27 | 2010-04-27 | Vaccines for protecting against influenza |
Publications (1)
Publication Number | Publication Date |
---|---|
USH2284H1 true USH2284H1 (en) | 2013-09-03 |
Family
ID=42244451
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/768,653 Abandoned USH2283H1 (en) | 2009-04-27 | 2010-04-27 | Vaccines for protecting against influenza |
US12/768,662 Abandoned USH2284H1 (en) | 2009-04-27 | 2010-04-27 | Vaccines for protecting against influenza |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/768,653 Abandoned USH2283H1 (en) | 2009-04-27 | 2010-04-27 | Vaccines for protecting against influenza |
Country Status (10)
Country | Link |
---|---|
US (2) | USH2283H1 (en) |
EP (1) | EP2424565A1 (en) |
JP (1) | JP2012525370A (en) |
KR (1) | KR20120027276A (en) |
CN (1) | CN102548577A (en) |
BE (1) | BE1019643A3 (en) |
CA (1) | CA2763816A1 (en) |
DE (1) | DE102010018462A1 (en) |
FR (1) | FR2949344A1 (en) |
WO (1) | WO2010125461A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102548577A (en) * | 2009-04-27 | 2012-07-04 | 诺华有限公司 | Adjuvanted vaccines for protecting against influenza |
CN103221064B (en) * | 2011-11-23 | 2014-12-03 | 苏州工业园区唯可达生物科技有限公司 | Immune methods against influenza viruses and combinatorial vaccines thereof |
GB201205189D0 (en) * | 2012-03-23 | 2012-05-09 | Glaxosmithkline Biolog Sa | Novel medical use |
CN103784953B (en) * | 2012-10-26 | 2018-04-10 | 上海医药工业研究院 | Oil-in-water type Submicron Emulsion as vaccine adjuvant and preparation method thereof |
WO2015140138A1 (en) * | 2014-03-17 | 2015-09-24 | Glaxosmithkline Biologicals Sa | Oil/surfactant mixtures for self-emulsification |
EP3157557A1 (en) | 2014-06-20 | 2017-04-26 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Polyvalent influenza virus-like particles (vlps) and use as vaccines |
US10220086B2 (en) | 2014-12-19 | 2019-03-05 | Oregon Health & Science University | Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza |
CA3054578A1 (en) * | 2017-02-27 | 2018-08-30 | Flugen, Inc. | Immunogenic compositions against influenza |
MX2019014943A (en) | 2018-12-12 | 2020-08-06 | Cambridge Tech Llc | Universal influenza vaccine. |
WO2021173965A1 (en) * | 2020-02-28 | 2021-09-02 | Massachusetts Institute Of Technology | Identification of variable influenza residues and uses thereof |
CN114010778A (en) * | 2021-10-21 | 2022-02-08 | 广州一品红制药有限公司 | Oil-in-water type vaccine adjuvant |
Citations (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
US4689338A (en) | 1983-11-18 | 1987-08-25 | Riker Laboratories, Inc. | 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use |
US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
US4988815A (en) | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
US5011828A (en) | 1985-11-15 | 1991-04-30 | Michael Goodman | Immunostimulating guanine derivatives, compositions and methods |
WO1992015582A1 (en) | 1991-03-01 | 1992-09-17 | Minnesota Mining And Manufacturing Company | 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES |
US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
US5266575A (en) | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
WO1995018861A1 (en) | 1994-01-11 | 1995-07-13 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Influenza vaccine |
US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
US5494916A (en) | 1993-07-15 | 1996-02-27 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]pyridin-4-amines |
WO1996037624A1 (en) | 1993-09-13 | 1996-11-28 | Mg-Pmc, L.L.C | A method for producing influenza hemagglutinin multivalent vaccines |
US5658731A (en) | 1990-04-09 | 1997-08-19 | Europaisches Laboratorium Fur Molekularbiologie | 2'-O-alkylnucleotides as well as polymers which contain such nucleotides |
WO1997037000A1 (en) | 1996-04-01 | 1997-10-09 | Chiron Behring Gmbh & Co. | Animal cells and processes for the replication of influenza viruses |
WO1997037001A1 (en) | 1996-04-01 | 1997-10-09 | Chiron Behring Gmbh & Co. | Processes for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process |
WO1998046262A1 (en) | 1997-04-16 | 1998-10-22 | Connaught Laboratories, Inc. | Anti-influenza compositions supplemented with neuraminidase |
US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
US5948410A (en) | 1997-04-09 | 1999-09-07 | Duphar International Research B.V. | Influenza vaccine |
WO1999064068A1 (en) | 1998-06-12 | 1999-12-16 | Mount Sinai School Of Medicine Of The City University Of New York | Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals |
US6083505A (en) | 1992-04-16 | 2000-07-04 | 3M Innovative Properties Company | 1H-imidazo[4,5-C]quinolin-4-amines as vaccine adjuvants |
WO2000060050A2 (en) | 1999-04-06 | 2000-10-12 | Wisconsin Alumni Research Foundation | Recombinant influenza viruses for vaccines and gene therapy |
WO2001004333A1 (en) | 1999-07-14 | 2001-01-18 | Mount Sinai School Of Medicine Of New York University | In vitro reconstitution of segmented negative-strand rna viruses |
WO2001021151A1 (en) | 1999-09-24 | 2001-03-29 | Smithkline Beecham Biologicals S.A. | Intranasal influenza virus vaccine |
WO2001022992A2 (en) | 1999-09-30 | 2001-04-05 | Smithkline Beecham Biologicals S.A. | Influenza vaccine |
WO2001022972A2 (en) | 1999-09-25 | 2001-04-05 | University Of Iowa Research Foundation | Immunostimulatory nucleic acids |
WO2001064846A1 (en) | 2000-03-03 | 2001-09-07 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell |
WO2001083794A2 (en) | 2000-04-28 | 2001-11-08 | St. Jude Children's Research Hospital | Dna transfection system for the generation of infectious influenza virus |
WO2001085938A1 (en) | 2000-05-11 | 2001-11-15 | Institut National De La Recherche Agronomique | Modified es cells and es cell-specific gene |
WO2002018383A2 (en) | 2000-09-01 | 2002-03-07 | Chiron Corporation | Aza heterocyclic derivatives and their therapeutic use |
US6355271B1 (en) | 1999-02-03 | 2002-03-12 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
WO2002028422A2 (en) | 2000-10-02 | 2002-04-11 | Glaxosmithkline Biologicals S.A. | Split enveloped virus preparation for intranasal delivery |
US6440992B1 (en) | 1998-07-28 | 2002-08-27 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
WO2002067983A1 (en) | 2001-02-23 | 2002-09-06 | Glaxosmithkline Biologicals S.A. | Novel vaccine |
WO2002074336A2 (en) | 2001-02-23 | 2002-09-26 | Glaxosmithkline Biologicals S.A. | Influenza vaccine formulations for intradermal delivery |
US6468544B1 (en) | 1998-06-12 | 2002-10-22 | Mount Sinai School Of Medicine Of The City University Of New York | Interferon inducing genetically engineered attenuated viruses |
WO2002097072A2 (en) | 2001-05-30 | 2002-12-05 | Saechsisches Serumwerk Dresden Branch Of Smithkline Beecham Pharma Gmbh & Co. Kg | Influenza vaccine composition |
WO2003011223A2 (en) | 2001-07-31 | 2003-02-13 | Eisai Co., Ltd. | Immunomodulatory compounds and methods of use thereof |
WO2003023025A1 (en) | 2001-09-12 | 2003-03-20 | Chiron Behring Gmbh & Co. | Multiplication of viruses in a cell culture |
WO2003023021A2 (en) | 2001-09-12 | 2003-03-20 | Chiron Behring Gmbh & Co. | Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an mdck cell suspension culture |
WO2003043415A1 (en) | 2001-11-22 | 2003-05-30 | Vivalis | Exogenous protein expression system in an avian system |
US6605617B2 (en) | 2000-09-11 | 2003-08-12 | Chiron Corporation | Quinolinone derivatives |
WO2003076601A1 (en) | 2002-03-08 | 2003-09-18 | Vivalis | Avian cell lines for the production of useful substances |
WO2003082272A1 (en) | 2002-03-29 | 2003-10-09 | Chiron Corporation | Substituted benzazoles and use thereof as raf kinase inhibitors |
US6649372B1 (en) | 1998-09-14 | 2003-11-18 | Mount Sinai School Of Medicine Of New York University | Helper-free rescue of recombinant negative strand RNA virus |
US6656938B2 (en) | 2000-12-08 | 2003-12-02 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
US6660735B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
US6660747B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US6664260B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Heterocyclic ether substituted imidazoquinolines |
US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US6664264B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US6667312B2 (en) | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
WO2003105769A2 (en) | 2002-06-13 | 2003-12-24 | New York University | Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
US6677347B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
US6677348B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
WO2004018455A1 (en) | 2002-08-23 | 2004-03-04 | Chiron Corporation | Pyrrole based inhibitors of glycogen synthase kinase 3 |
US6743920B2 (en) | 2002-05-29 | 2004-06-01 | 3M Innovative Properties Company | Process for imidazo[4,5-c]pyridin-4-amines |
WO2004060308A2 (en) | 2002-12-27 | 2004-07-22 | Chiron Corporation | Thiosemicarbazones as anti-virals and immunopotentiators |
WO2004064715A2 (en) | 2003-01-23 | 2004-08-05 | M N L Pharma Limited | Polyhydroxylated pyrrolizidine |
WO2004064759A2 (en) | 2003-01-21 | 2004-08-05 | Chiron Corporation | Use of tryptanthrin compounds for immune potentiation |
US6800624B2 (en) | 1999-06-10 | 2004-10-05 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
WO2004087153A2 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of organic compounds for immunopotentiation |
FR2859633A1 (en) | 2003-09-15 | 2005-03-18 | Petrov Alexandr Alexandrovich | Synthetic immunogen for therapy and prophylaxis of addiction with narcotic and psychoactive substances |
US20050070556A1 (en) | 2001-11-27 | 2005-03-31 | Anadys Pharmaceuticals, Inc. | 3-B-D-ribofuranosylthiazolo [4,5-d] pyridimine nucleosides and uses thereof |
WO2005042728A2 (en) | 2003-11-03 | 2005-05-12 | Probiogen Ag | Immortalized avian cell lines for virus production |
US6924271B2 (en) | 2001-11-27 | 2005-08-02 | Anadys Pharmaceuticals, Inc. | 3-β-D-ribofuranosylthiazolo[4-5-d]pyridimine nucleosides and uses thereof |
US20050192248A1 (en) | 2003-10-08 | 2005-09-01 | Nyu Medical Center | Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases |
US20050215517A1 (en) | 1999-01-14 | 2005-09-29 | Rossignol Daniel P | Use of an anti-endotoxin drug in the prevention and treatment of disease |
WO2005102049A1 (en) | 2004-03-31 | 2005-11-03 | New York University | Novel synthetic c-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases |
WO2005113758A1 (en) | 2004-05-20 | 2005-12-01 | Id Biomedical Corporation | Process for the production of an influenza vaccine |
WO2005113756A1 (en) | 2004-05-14 | 2005-12-01 | Glaxosmithkline Biologicals S.A. | Method |
WO2006027698A1 (en) | 2004-09-09 | 2006-03-16 | Novartis Vaccines And Diagnostics Gmbh & Co Kg. | Decreasing potential iatrogenic risks associated with influenza vaccines |
WO2006067211A1 (en) | 2004-12-24 | 2006-06-29 | Solvay Pharmaceuticals B.V. | Rescue of influenza virus |
WO2006071563A2 (en) | 2004-12-23 | 2006-07-06 | Medimmune Vaccines, Inc. | Non-tumorigenic mdck cell line for propagating viruses |
WO2006108846A1 (en) | 2005-04-11 | 2006-10-19 | Vivalis | Process of manufacturing viral vaccines in suspension avian embryonic derived stem cell lines |
WO2007002008A2 (en) | 2005-06-21 | 2007-01-04 | Medimmune Vaccines, Inc. | Methods and compositions for expressing negative-sense viral rna in canine cells |
WO2007052163A2 (en) | 2005-11-01 | 2007-05-10 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment |
US20100010199A1 (en) * | 2006-09-11 | 2010-01-14 | Novartis Ag | Making influenza virus vaccines without using eggs |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
AU2006310163B2 (en) | 2005-11-04 | 2011-09-15 | Seqirus UK Limited | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
AR066405A1 (en) | 2007-04-20 | 2009-08-19 | Glaxosmithkline Biolog Sa | VACCINE |
GB0905570D0 (en) * | 2009-03-31 | 2009-05-13 | Novartis Ag | Combined vaccines |
CN102548577A (en) * | 2009-04-27 | 2012-07-04 | 诺华有限公司 | Adjuvanted vaccines for protecting against influenza |
-
2010
- 2010-04-27 CN CN2010800275269A patent/CN102548577A/en active Pending
- 2010-04-27 US US12/768,653 patent/USH2283H1/en not_active Abandoned
- 2010-04-27 WO PCT/IB2010/001007 patent/WO2010125461A1/en active Application Filing
- 2010-04-27 FR FR1053219A patent/FR2949344A1/en active Pending
- 2010-04-27 EP EP10719073A patent/EP2424565A1/en not_active Withdrawn
- 2010-04-27 BE BE2010/0259A patent/BE1019643A3/en not_active IP Right Cessation
- 2010-04-27 DE DE102010018462A patent/DE102010018462A1/en not_active Withdrawn
- 2010-04-27 JP JP2012507843A patent/JP2012525370A/en not_active Withdrawn
- 2010-04-27 KR KR1020117028417A patent/KR20120027276A/en not_active Application Discontinuation
- 2010-04-27 US US12/768,662 patent/USH2284H1/en not_active Abandoned
- 2010-04-27 CA CA2763816A patent/CA2763816A1/en not_active Abandoned
Patent Citations (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4689338A (en) | 1983-11-18 | 1987-08-25 | Riker Laboratories, Inc. | 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use |
US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
US5011828A (en) | 1985-11-15 | 1991-04-30 | Michael Goodman | Immunostimulating guanine derivatives, compositions and methods |
US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
US4988815A (en) | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
US5658731A (en) | 1990-04-09 | 1997-08-19 | Europaisches Laboratorium Fur Molekularbiologie | 2'-O-alkylnucleotides as well as polymers which contain such nucleotides |
WO1992015582A1 (en) | 1991-03-01 | 1992-09-17 | Minnesota Mining And Manufacturing Company | 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES |
US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
US5525612A (en) | 1991-09-04 | 1996-06-11 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo-[4,5-c]quinolin-4-amines |
US5346905A (en) | 1991-09-04 | 1994-09-13 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo-[4,5-C]quinolin-4-amines |
US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US5266575A (en) | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
US6083505A (en) | 1992-04-16 | 2000-07-04 | 3M Innovative Properties Company | 1H-imidazo[4,5-C]quinolin-4-amines as vaccine adjuvants |
US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
US5494916A (en) | 1993-07-15 | 1996-02-27 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]pyridin-4-amines |
WO1996037624A1 (en) | 1993-09-13 | 1996-11-28 | Mg-Pmc, L.L.C | A method for producing influenza hemagglutinin multivalent vaccines |
WO1995018861A1 (en) | 1994-01-11 | 1995-07-13 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Influenza vaccine |
US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
WO1997037000A1 (en) | 1996-04-01 | 1997-10-09 | Chiron Behring Gmbh & Co. | Animal cells and processes for the replication of influenza viruses |
WO1997037001A1 (en) | 1996-04-01 | 1997-10-09 | Chiron Behring Gmbh & Co. | Processes for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process |
US5948410A (en) | 1997-04-09 | 1999-09-07 | Duphar International Research B.V. | Influenza vaccine |
EP0870508B1 (en) | 1997-04-09 | 2000-11-08 | Duphar International Research B.V | Influenza vaccine |
WO1998046262A1 (en) | 1997-04-16 | 1998-10-22 | Connaught Laboratories, Inc. | Anti-influenza compositions supplemented with neuraminidase |
WO1999064068A1 (en) | 1998-06-12 | 1999-12-16 | Mount Sinai School Of Medicine Of The City University Of New York | Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals |
US6468544B1 (en) | 1998-06-12 | 2002-10-22 | Mount Sinai School Of Medicine Of The City University Of New York | Interferon inducing genetically engineered attenuated viruses |
US6440992B1 (en) | 1998-07-28 | 2002-08-27 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
US6627640B2 (en) | 1998-07-28 | 2003-09-30 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
US6809203B2 (en) | 1998-07-28 | 2004-10-26 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-C]-quinolin-4-amines and analogs thereof |
US6703402B2 (en) | 1998-07-28 | 2004-03-09 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
US6649372B1 (en) | 1998-09-14 | 2003-11-18 | Mount Sinai School Of Medicine Of New York University | Helper-free rescue of recombinant negative strand RNA virus |
US20050215517A1 (en) | 1999-01-14 | 2005-09-29 | Rossignol Daniel P | Use of an anti-endotoxin drug in the prevention and treatment of disease |
US6355271B1 (en) | 1999-02-03 | 2002-03-12 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
WO2000060050A2 (en) | 1999-04-06 | 2000-10-12 | Wisconsin Alumni Research Foundation | Recombinant influenza viruses for vaccines and gene therapy |
US6800624B2 (en) | 1999-06-10 | 2004-10-05 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
WO2001004333A1 (en) | 1999-07-14 | 2001-01-18 | Mount Sinai School Of Medicine Of New York University | In vitro reconstitution of segmented negative-strand rna viruses |
WO2001021151A1 (en) | 1999-09-24 | 2001-03-29 | Smithkline Beecham Biologicals S.A. | Intranasal influenza virus vaccine |
WO2001022972A2 (en) | 1999-09-25 | 2001-04-05 | University Of Iowa Research Foundation | Immunostimulatory nucleic acids |
WO2001022992A2 (en) | 1999-09-30 | 2001-04-05 | Smithkline Beecham Biologicals S.A. | Influenza vaccine |
WO2001064846A1 (en) | 2000-03-03 | 2001-09-07 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell |
EP1260581A1 (en) | 2000-03-03 | 2002-11-27 | Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute | Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell |
WO2001083794A2 (en) | 2000-04-28 | 2001-11-08 | St. Jude Children's Research Hospital | Dna transfection system for the generation of infectious influenza virus |
WO2001085938A1 (en) | 2000-05-11 | 2001-11-15 | Institut National De La Recherche Agronomique | Modified es cells and es cell-specific gene |
WO2002018383A2 (en) | 2000-09-01 | 2002-03-07 | Chiron Corporation | Aza heterocyclic derivatives and their therapeutic use |
US6605617B2 (en) | 2000-09-11 | 2003-08-12 | Chiron Corporation | Quinolinone derivatives |
WO2002028422A2 (en) | 2000-10-02 | 2002-04-11 | Glaxosmithkline Biologicals S.A. | Split enveloped virus preparation for intranasal delivery |
US6667312B2 (en) | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US6664264B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US6677348B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
US6670372B2 (en) | 2000-12-08 | 2003-12-30 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
US6683088B2 (en) | 2000-12-08 | 2004-01-27 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
US6656938B2 (en) | 2000-12-08 | 2003-12-02 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
US6677347B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
US6664260B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Heterocyclic ether substituted imidazoquinolines |
US6660735B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
US6660747B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
WO2002067983A1 (en) | 2001-02-23 | 2002-09-06 | Glaxosmithkline Biologicals S.A. | Novel vaccine |
WO2002074336A2 (en) | 2001-02-23 | 2002-09-26 | Glaxosmithkline Biologicals S.A. | Influenza vaccine formulations for intradermal delivery |
WO2002097072A2 (en) | 2001-05-30 | 2002-12-05 | Saechsisches Serumwerk Dresden Branch Of Smithkline Beecham Pharma Gmbh & Co. Kg | Influenza vaccine composition |
WO2003011223A2 (en) | 2001-07-31 | 2003-02-13 | Eisai Co., Ltd. | Immunomodulatory compounds and methods of use thereof |
WO2003023021A2 (en) | 2001-09-12 | 2003-03-20 | Chiron Behring Gmbh & Co. | Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an mdck cell suspension culture |
WO2003023025A1 (en) | 2001-09-12 | 2003-03-20 | Chiron Behring Gmbh & Co. | Multiplication of viruses in a cell culture |
WO2003043415A1 (en) | 2001-11-22 | 2003-05-30 | Vivalis | Exogenous protein expression system in an avian system |
US6924271B2 (en) | 2001-11-27 | 2005-08-02 | Anadys Pharmaceuticals, Inc. | 3-β-D-ribofuranosylthiazolo[4-5-d]pyridimine nucleosides and uses thereof |
US20050070556A1 (en) | 2001-11-27 | 2005-03-31 | Anadys Pharmaceuticals, Inc. | 3-B-D-ribofuranosylthiazolo [4,5-d] pyridimine nucleosides and uses thereof |
US6924293B2 (en) | 2001-12-21 | 2005-08-02 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
US6888000B2 (en) | 2001-12-21 | 2005-05-03 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
WO2003076601A1 (en) | 2002-03-08 | 2003-09-18 | Vivalis | Avian cell lines for the production of useful substances |
WO2003082272A1 (en) | 2002-03-29 | 2003-10-09 | Chiron Corporation | Substituted benzazoles and use thereof as raf kinase inhibitors |
US6743920B2 (en) | 2002-05-29 | 2004-06-01 | 3M Innovative Properties Company | Process for imidazo[4,5-c]pyridin-4-amines |
WO2003105769A2 (en) | 2002-06-13 | 2003-12-24 | New York University | Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
WO2004018455A1 (en) | 2002-08-23 | 2004-03-04 | Chiron Corporation | Pyrrole based inhibitors of glycogen synthase kinase 3 |
WO2004060308A2 (en) | 2002-12-27 | 2004-07-22 | Chiron Corporation | Thiosemicarbazones as anti-virals and immunopotentiators |
WO2004064759A2 (en) | 2003-01-21 | 2004-08-05 | Chiron Corporation | Use of tryptanthrin compounds for immune potentiation |
WO2004064715A2 (en) | 2003-01-23 | 2004-08-05 | M N L Pharma Limited | Polyhydroxylated pyrrolizidine |
WO2004087153A2 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of organic compounds for immunopotentiation |
FR2859633A1 (en) | 2003-09-15 | 2005-03-18 | Petrov Alexandr Alexandrovich | Synthetic immunogen for therapy and prophylaxis of addiction with narcotic and psychoactive substances |
US20050192248A1 (en) | 2003-10-08 | 2005-09-01 | Nyu Medical Center | Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases |
WO2005042728A2 (en) | 2003-11-03 | 2005-05-12 | Probiogen Ag | Immortalized avian cell lines for virus production |
WO2005102049A1 (en) | 2004-03-31 | 2005-11-03 | New York University | Novel synthetic c-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases |
WO2005113756A1 (en) | 2004-05-14 | 2005-12-01 | Glaxosmithkline Biologicals S.A. | Method |
WO2005113758A1 (en) | 2004-05-20 | 2005-12-01 | Id Biomedical Corporation | Process for the production of an influenza vaccine |
WO2006027698A1 (en) | 2004-09-09 | 2006-03-16 | Novartis Vaccines And Diagnostics Gmbh & Co Kg. | Decreasing potential iatrogenic risks associated with influenza vaccines |
WO2006071563A2 (en) | 2004-12-23 | 2006-07-06 | Medimmune Vaccines, Inc. | Non-tumorigenic mdck cell line for propagating viruses |
WO2006067211A1 (en) | 2004-12-24 | 2006-06-29 | Solvay Pharmaceuticals B.V. | Rescue of influenza virus |
WO2006108846A1 (en) | 2005-04-11 | 2006-10-19 | Vivalis | Process of manufacturing viral vaccines in suspension avian embryonic derived stem cell lines |
WO2007002008A2 (en) | 2005-06-21 | 2007-01-04 | Medimmune Vaccines, Inc. | Methods and compositions for expressing negative-sense viral rna in canine cells |
WO2007052163A2 (en) | 2005-11-01 | 2007-05-10 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment |
US20100010199A1 (en) * | 2006-09-11 | 2010-01-14 | Novartis Ag | Making influenza virus vaccines without using eggs |
Non-Patent Citations (104)
Title |
---|
Andrianov et al. 91998) Biomaterials 19:109-115. |
Banzhoff (2000) Immunology Letters 71:91-96. |
Beignon et al. (2002) Infect Immun 70: 3012-3019. |
Brands et al. (1999) Dev Biol Stand 98:93-100. |
Briggs (1991) J Parenter Sci Technol. 45:7-12. |
Bright et al. (2008) PLoS ONE 3:e1501. |
Bruhl et al. (2000) Vaccine 19:1149-58. |
Caillet et al. (2010) Vaccine 28:3076-3079. |
Centers for Diseases Control and Prevention. (May 22, 2009) MMWR 58(19):521-56. |
Chen et al. (2003) Vaccine 21:2830-2836. |
Chen et al. Virol. 2006, vol. 345, No. 2, pp. 416-423. * |
Clark et al. (2009) NEJM 361:2424-35. |
Cooper (1995) Pharm Biotechnol 6:559-80. |
Couceiro & Baum (1994) Mem Inst Oswaldo Cruz 89(4):587-91. |
Crevar & Ross (2008) Virology Journal 5(131), 9 pages. |
de Jong et al. (2003) Dev. Biol (Basel) 115:63-73. |
De Libero et al. (2005) Nature Reviews Immunology 5:485-496. |
Del Giudice et al. (2009) Sci Transl Med. 1(12):1-3. |
Dolin et al. (1977) J Infect. Dis. 136(Suppl.):S435-S442. |
Doroshenko & Halperin (2009) Expert Rev Vaccines 8:679-88. |
Dyakonova et al. (2004) Int Immunopharmacol 4(13):1615-23. |
Efferson et al. (2006) J Viral. 80(1):383-94. |
Ershler et al. (2007) Ann N Y Acad Sci. 1112:375-84. |
Evans et al. (2003) Expert Rev Vaccines 2:219-229. |
Galli et al. (2009) PNAS USA 106:7962-7. |
Gambaryan & Matrosovich (1992) J Virol Methods 39(1-2):111-23. |
Garten et al. (2009) Science 325:197-201. |
GenBank sequence GI:325176, (Aug. 2, 1993), 1 page. |
GenBank sequence GI:325237, (Aug. 2, 1993), 1 page. |
Gennaro (2000) Remington: The Science and Practice of Pharmacy. 20th edition, ISBN: 0683306472. |
Goff et al (2004) J Am. Chem. Soc. 126:13602-13603. |
Greenbaum et at. (2004) Vaccine 22:2566-2577. |
Greenberg et al. (2009) NEJM 361(25):2405-2413. |
Guidance for Industry: Bioanalytical Method Validation, (May 2001). U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Veterinary Medicine (CVM). |
Halperin et al. (1979) Am J Public Health 69:1247-1250. |
Halperin et al. (2002) Vaccine 20:1240-7. |
Hehme et al. (2004) Virus Res. 103(1-2):163-171. |
Herbert et al. (1979) J Infect Dis 140:234-238. |
Herlocher et al. (2004) J Infect Dis 190(9):1627-30. |
Hoffmann et al. (2000) Virology 267(2):310-7. |
Hoffmann et al. (2002) Vaccine 20:3165-3170. |
Huckriede et al. (2003) Methods Enzymol 373:74-91. |
Hussain et al. (2010) Vaccine 28(22):3848-3855. |
Ji et al. (2002) Biotechniques 32:1162-7. |
Jin et al. (2003) Virology 306:18-24. |
Johnson et al. (1999) Bioorg Med Chem Lett 9:2273-2278. |
Jones (2003) Curr Opin Invest Drugs 4:214-218. |
Keitel et al. (1996) Clin Diagn Lab Immunol 3:507-10. |
Kistner et al. (1998) Vaccine 16:960-8. |
Kistner et al. (1999) Dev Biol Stand 98:101-10. |
Kistner et al. (2010) PLoS ONE 5(2): e9349. |
Kitikoon et al. (2010) Vaccine 28:523-31. |
Lahijani et al. (1998) Hum Gene Ther. 9:1173-80. |
Liu et al. (2003) Virology 314:580-90. |
Lokteff et al. (2001) Biologicals 29:123-32. |
Lundblad (2001) Biotechnology and Applied Biochemistry 34:195-7. |
Mann et al. (2004) Vaccine 22:2425-9. |
Massab et al. Rev Med Virol. 1999 Oct.-Dec.;9 (4):237-244. * |
Mastrosovich et al. (1999) J Virol 73:1146-55. |
McCullers et al. (1999) J Virol 73:7343-8. |
Meraldi et al. (2003) Vaccine 21:2485-2491. |
Munster et al. (2009) Science 325:481-3. |
Neumann et al. (2005) Proc Natl Acad Sci USA 102:16825-29. |
Nony et al. (2001) Vaccine 27:3645-51. |
Oki et al. (2004) J Clin. Investig. 113:1631-1640. |
Ozaki et al. (2004) J. Virol. 78:1851-7. |
Pajak et al. (2003) Vaccine 21:836-842. |
Partidos et al. (1999) Immunol Lett 67:209-216. |
Pau et al. (2001) Vaccine 19:2716-21. |
Payne et al. (1998) Adv Drug Delivery Review 31:185-196. |
Peppeloni et al. (2003) Expert Rev Vaccines 2:285-293. |
Piascik (2003) J am Pharm Assoc (Wash DC). 43:728-30. |
Pine et al. (2002) J Control Release 85:263-270. |
Pizza et al. (2000) Int J Med Microbiol 290:455-461. |
Pizza et al. (2001) Vaccine 19:2534-2541. |
Plotkin & Orenstein, eds., (2004) Vaccines. 4th edition, ISBN: 0-7216-9688-0. |
Poole & Mussett (1989) J Biol Stand 17:161-71. |
Poole et al. (1997) J Endotoxin Res 4:221-31. |
Potter & Oxford (1979) Br Med Bull 35:69-75. |
Powell & Newman, eds., (1995). Vaccine Design: The Subunit and Adjuvant Approach Plenum Press (ISBN 0-306-44867-XP). |
Quan et al. (2010) PLoS ONE 5(2):e9161. |
Roman et al. (2010) Vaccine 28:1740-45. |
Ryan et al. (1999) Infect Immun 67:6270-6280. |
Scharton-Kersten et al. (2000) Infect Immun 68:5306-5313. |
Schellack et al. (2006) Vaccine 24:5461-72. |
Signorelli & Hadden (2003) Int Immunopharmacol 3(8):1177-86. |
Smith et al. (2009) Nature 459:1122-5. |
Snyder et al. J. Virol. 1988, vol. 62, No. 2, pp. 488-495. * |
Stanley (2002) Clin Exp Dermatol 27:571-577. |
Stephenson et al. (2003) Vaccine 21:1687-93. |
Stevens et al. (2006) J Mol Biol 355:1143-55. |
Subbarao et al. (2003) Virology 305:192-200. |
Talbot et al. (2008) Vaccine 26:4057-61. |
Tebbey et al. (2000) Vaccine 18:2723-34. |
Treanor et al. (1996) J Infect Dis 173:1467-70. |
Tree et al. (2001) Vaccine 19:3444-50. |
Vajo et al. (2010) Lancet 375:49-55. |
Vasilakos et al. (2000) Cell Immunol. 204(1):64-74. |
Webby et al. (2004) Lancet 363:1099-103. |
Wong et al. (2003) J Clin Pharmacol 43(7):735-42. |
Wu et al. (2004) Antiviral Res. 64(2):79-83. |
Yang et al. (2004) Angew. Chem. Int. Ed. 43:3818-3822. |
Zangwill et al. (2008) J Infect Dis. 197(4):580-3. |
Zurbriggen et al. (2003) Expert Rev Vaccines 2:295-304. |
Also Published As
Publication number | Publication date |
---|---|
KR20120027276A (en) | 2012-03-21 |
WO2010125461A1 (en) | 2010-11-04 |
JP2012525370A (en) | 2012-10-22 |
BE1019643A3 (en) | 2012-09-04 |
EP2424565A1 (en) | 2012-03-07 |
FR2949344A1 (en) | 2011-03-04 |
CN102548577A (en) | 2012-07-04 |
CA2763816A1 (en) | 2010-11-04 |
DE102010018462A1 (en) | 2011-04-07 |
USH2283H1 (en) | 2013-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USH2284H1 (en) | Vaccines for protecting against influenza | |
JP7427648B2 (en) | Production of influenza virus vaccine without eggs | |
US20230398203A1 (en) | Soluble needle arrays for delivery of influenza vaccines | |
US20180207258A1 (en) | Adjuvanted influenza vaccines for pediatric use | |
EP1951299B1 (en) | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators | |
US10329537B2 (en) | Influenza virus reassortment | |
JP6279503B2 (en) | Influenza virus reassembly | |
EP2493912B1 (en) | High titer recombinant influenza viruses with enhanced replication in vero cells | |
US11013795B2 (en) | Antigenically matched influenza vaccines | |
US7959931B2 (en) | Influenza vaccines extemporaneously adsorbed to aluminium adjuvants | |
JP6421128B2 (en) | Rear sortant influenza A virus | |
US20200172877A1 (en) | Influenza virus reassortment | |
US10030231B2 (en) | Influenza virus reassortment | |
JP2023502650A (en) | Methods for Producing Genetically Reassorted Influenza Viruses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NOVARTIS AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS VACCINES AND DIAGNOSTICS GMBH;REEL/FRAME:025645/0576 Effective date: 20101119 Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC., CALIFORNI Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:STOHR, KLAUS;DORMITZER, PHILIP;SIGNING DATES FROM 20100825 TO 20100907;REEL/FRAME:025645/0067 Owner name: NOVARTIS AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS VACCINES & DIAGNOSTICS, INC.;REEL/FRAME:025645/0269 Effective date: 20101020 Owner name: NOVARTIS VACCINES AND DIAGNOSTICS GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BROEKER, MICHAEL;REEL/FRAME:025645/0463 Effective date: 20100810 |
|
AS | Assignment |
Owner name: NOVARTIS AG, SWITZERLAND Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE TYPO ON SERIAL NO. 12/768622 TO 12/768662 PREVIOUSLY RECORDED ON REEL 025645 FRAME 0576. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF NOVARTIS VACCINES AND DIAGNOTICS GMBH TO NOVARTIS AG;ASSIGNOR:NOVARTIS VACCINES AND DIAGNOSTICS GMBH;REEL/FRAME:026263/0152 Effective date: 20101119 Owner name: NOVARTIS AG, SWITZERLAND Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE TYPO ON SERIAL NO. 12/768622 TO 12/768662 PREVIOUSLY RECORDED ON REEL 025645 FRAME 0269. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF NOVARTIS VACCINES AND DIAGNOSTICS, INC. TO NOVARTIS AG;ASSIGNOR:NOVARTIS VACCINES & DIAGNOSTICS, INC.;REEL/FRAME:026263/0105 Effective date: 20101020 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: SEQIRUS UK LIMITED, ENGLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVARTIS AG;REEL/FRAME:039335/0937 Effective date: 20150731 |